2013,International Journal of Pharmaceutics Chapter Nanoformulations targeting Alzheimer's disease 4.1.5Immunoliposomes Recently, the trend is to developliposomesspecific to malignant tissues, which is the next
Present advances in liposome nanotechnology drug carriers have resulted in better treatment of multidrug resistant cancers and lower cardio toxicity [48]. Many types of drugs have been employed in this lipid-based structure such as liposomal formulations of daunorubicin (Dauno Xome) and anthrax ...
Incorporation efficiency was high (89–93% of the amount of DNA used) in all four formulations tested and incorporated DNA was shown to be resistant to displacement in the presence of the competing anionic sodium dodecyl sulphate molecules. This is consistent with the notion that most of the ...
The results showed that the liposome formulations (eLipo anti-PD-L1, and eLipo anti-PD-L1 dox) were stable at 4°C, and the leakage of doxorubicin was kept at 5% or so (Supplementary Fig. 3a–c). The release profiles of doxorubicin from eLipo anti-PD-L1 dox were further ...
The administration route of these liposomal drug formulations can be intravenous4, intramuscular, epidural5, intratracheal or intrabronchial6. Other delivery routes have also been investigated (e.g., oral7, dermal or transdermal8), although they are less frequently employed in association with ...
Liposomal formulations in case of passive targeting show a higher localization of drug inside the tumor cells due to EPR effect. Apart from the passive targeting, the third generation liposomes also have the active and physicochemical targeting potential. Functionalized liposomes can deliver the drug ...
Rivastigmine concentration and exposure are enhanced by liposomal formulations compared to nonliposomal formulations applied for drug delivery to the brain for the treatment of AD.99,100 Furthermore, liposomes offer hope due to their targeting ability to Aβ, which is responsible for the amyloid plaqu...
As seen from the data in Table 4 in Example 6, high blood/RES ratios were achieved in substantially all of the liposome formulations, independent of the extent of lipid unsaturation in the bulk PC phospholipid, and no systematic trend, as a function of degree of lipid saturation, was ...
<div p-id="p-0001">The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ran
Liposomal formulations can prolong the circulatory half-lives of arachidonic acid metabolites, e.g., prostaglandins, and can help avoid their deactivation in the lungs. Accordingly, such liposomal formulations can provide therapeutically useful alternatives for prostaglandin treatment. Mizishuma et al. (J...